← 產業報告目錄

Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-10-14頁數 377報告編號 BT4883

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The molecular cytogenetics market is expected to reach USD 1.43 billion in 2030 from USD 1.02 billion in 2025, at a CAGR of 7.1% during the forecast period. The market is driven by a rising prevalence of cancer and genetic disorders, mainly among older adults. The growing application of molecular cytogenetic tests for accurate diagnosis and disease management also plays a crucial role. Furthermore, the emergence of targeted therapies and their integration into personalized medicine are further driving market growth. Nonetheless, the high expenses associated with advanced molecular cytogenetic techniques and the requirement for skilled professionals continue to be major barriers to market expansion. “Testing kits segment is expected to grow at the highest CAGR during the forecast period” The testing kits segment is growing at the highest CAGR in the molecular cytogenetics market due to its ease of use, reproducibility, and ability to deliver rapid, accurate results. These kits, including CGH arrays and FISH probe panels, enable standardized detection of chromosomal abnormalities and genetic variations across clinical and research laboratories. By leveraging pre-validated assays and integrated analysis tools, testing kits offer reliable, high-throughput solutions that support oncology, prenatal testing, and genetic disorder diagnostics. Their convenience, accuracy, and scalability make them essential for efficient cytogenetic testing, driving their strong adoption in the market. “Cancer application segment holds the largest share of the market” The cancer applications segment accounts for the largest share of the molecular cytogenetics market. This growth is primarily driven by the rising incidence of cancer worldwide, particularly among the aging population, which is more susceptible to malignancies. Genetic changes and chromosomal abnormalities are major contributors to tumor development, increasing the demand for molecular cytogenetic testing in oncology. Techniques such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) enable the precise detection of these abnormalities, facilitating accurate diagnosis, classification of tumor types, and monitoring of disease progression. Furthermore, increasing investments in cancer research, improvements in healthcare infrastructure, and growing awareness of the benefits of early detection and genetic profiling are contributing to the robust growth of this segment across clinical and research settings globally. “US is expected to grow at the highest CAGR during the forecast period” The US is experiencing the highest growth rate in the molecular cytogenetics market due to several factors. The presence of leading cytogenetics companies, advanced research infrastructure, and a large patient base are major drivers of market growth in the country. Additionally, rising adoption of molecular cytogenetic testing in oncology, prenatal screening, and genetic disorder diagnostics is fueling demand. Supportive healthcare regulations, increased funding for genomic research, and the growing focus on precision medicine further contribute to the expansion of the molecular cytogenetics market in the US. Additionally, the widespread adoption of molecular cytogenetic techniques, such as FISH and CGH, for the accurate detection of chromosomal abnormalities has further supported the growth of molecular cytogenetics. Extensive government and private funding for biomedical research and oncology accelerates innovation and the deployment of cutting-edge testing platforms. The region’s stringent regulatory framework ensures product quality and reliability, further strengthening trust in molecular cytogenetic solutions and solidifying North America’s dominant position globally. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5% F. Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Revvity (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), GeneDx, LLC (US), Insight Molecular Diagnostics Inc. (US), BioView (Israel), Oxford Gene Technology IP Limited (UK), Applied Spectral Imaging, Inc. (US), CytoTest Inc. (US), KROMATID (US), Genial Genetic Solutions Ltd. (UK), Cytognomix Inc. (Canada), MetaSystems (Germany), SciGene Corporation (US), Biomodal (UK), Biocare Medical, LLC (US), BioDot (US), and OncoDNA (Belgium) are some of the key companies offering molecular cytogenetics products. Research Coverage This research report categorizes the molecular cytogenetics market by product & service (kits & reagents [testing kits, probes, fluorescent affinity reagents, other kits & reagents], instruments, consumables, software & services), technique (comparative genomic hybridization [array-based comparative genomic hybridization, standard comparative genomic hybridization], fluorescence in-situ hybridization, chromogenic in-situ hybridization, other techniques), application (cancer, genetic disorders, personalized medicine and other applications), end user (clinical & research laboratories, academic & research institutes, pharmaceutical & biotechnology companies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the molecular cytogenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the molecular cytogenetics market. This report also includes a competitive analysis of emerging startups in the molecular cytogenetics industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, and increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments and unfavourable reimbursement scenario), opportunities (untapped emerging markets), and challenges (transition from FISH to array-based techniques) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the molecular cytogenetics market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including F. Hoffman-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), among others offering products and services for molecular cytogenetics market. Other companies include Applied Spectral Imaging Inc. (US), Biomodal (UK), Biocare Medical, LLC (US), OncoDNA (Belgium), among others, for the molecular cytogenetics market
目錄 Table of Contents
1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 36 1.3.4 CURRENCY CONSIDERED 36 1.4 STAKEHOLDERS 37 1.5 SUMMARY OF CHANGES 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 39 2.1.1.1 Key sources of secondary data 39 2.1.1.2 Key objectives of secondary research 39 2.1.2 PRIMARY DATA 40 2.1.2.1 Breakdown of primaries 40 2.1.2.2 Key objectives of primary research 40 2.2 MARKET SIZE ESTIMATION 41 2.2.1 GLOBAL MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION, 2024 41 2.2.1.1 Revenue share analysis (bottom-up approach) 41 2.2.1.2 Secondary data & primary interviews 43 2.2.1.2.1 Insights of primary experts 44 2.2.1.3 MnM repository analysis 44 2.2.2 SEGMENTAL MARKET ASSESSMENT: TOP-DOWN APPROACH 45 2.3 MARKET GROWTH RATE PROJECTION 46 2.4 DATA TRIANGULATION 48 2.5 STUDY ASSUMPTIONS 49 2.6 RESEARCH LIMITATIONS 50 2.7 RISK ANALYSIS 50 3 EXECUTIVE SUMMARY 51 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS 55 3.3 DISRUPTIVE TRENDS SHAPING MOLECULAR CYTOGENETICS MARKET 56 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 56 3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 57 4 PREMIUM INSIGHTS 58 4.1 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION AND COUNTRY 58 4.2 MOLECULAR CYTOGENETICS MARKET SHARE, BY END USER, 2024 59 4.3 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 62 4.6 VC/PRIVATE EQUITY INVESTMENT TRENDS 62 5 MARKET OVERVIEW 64 5.1 INTRODUCTION 64 5.2 MARKET DYNAMICS 64 5.2.1 DRIVERS 65 5.2.1.1 Advancement and adoption of high-resolution techniques 65 5.2.1.2 Growing focus on targeted cancer treatment 66 5.2.1.3 Increasing penetration of molecular cytogenetics in clinical pathological testing 67 5.2.2 RESTRAINTS 68 5.2.2.1 High cost of advanced instruments 68 5.2.2.2 Unfavorable reimbursement scenario for advanced diagnostic tests 68 5.2.3 OPPORTUNITIES 69 5.2.3.1 Untapped emerging markets 69 5.2.4 CHALLENGES 69 5.2.4.1 Transition from FISH to array-based molecular cytogenetic techniques in diagnostic and research communities 69 5.3 UNMET NEEDS & WHITE SPACES 70 6 INDUSTRY TRENDS 71 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71 6.2 CASE STUDY ANALYSIS 71 6.2.1 MOSAIC TETRASOMY 9P TO BE DETECTED BY CNV-SEQ IN PRENATAL DIAGNOSIS 71 6.2.2 PRENATAL DETECTION OF 15Q21.3 AND 16P11.2 MICRODUPLICATION SYNDROMES USING CNV-SEQ AND WES 72 6.2.3 INTEGRATED CNV-SEQ AND KARYOTYPING IN LARGE PRENATAL COHORT FOR CHROMOSOMAL ABNORMALITY DETECTION 72 6.3 TECHNOLOGY ANALYSIS 72 6.3.1 KEY TECHNOLOGIES 73 6.3.1.1 Optical genome mapping 73 6.3.1.2 Next-generation sequencing 73 6.3.2 COMPLEMENTARY TECHNOLOGIES 73 6.3.2.1 CRISPR-based editing 73   6.4 PRICING ANALYSIS 74 6.4.1 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER, 2022–2024 74 6.4.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 76 6.5 PATENT ANALYSIS 79 6.5.1 METHODOLOGY 79 6.5.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 79 6.5.3 LIST OF KEY PATENTS 81 6.6 TRADE ANALYSIS 82 6.6.1 IMPORT DATA FOR HS CODE 3822.00, 2020–2024 82 6.6.2 EXPORT DATA FOR HS CODE 3822.00, 2020–2024 83 6.7 VALUE CHAIN ANALYSIS 84 6.8 ECOSYSTEM ANALYSIS 85 6.8.1 ROLE IN ECOSYSTEM 88 6.8.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 88 6.9 PORTER’S FIVE FORCES ANALYSIS 89 6.9.1 INTENSITY OF COMPETITIVE RIVALRY 90 6.9.2 BARGAINING POWER OF SUPPLIERS 91 6.9.3 BARGAINING POWER OF BUYERS 91 6.9.4 THREAT OF SUBSTITUTES 91 6.9.5 THREAT OF NEW ENTRANTS 91 6.10 KEY STAKEHOLDERS & BUYING CRITERIA 92 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 92 6.10.2 KEY BUYING CRITERIA 93 6.11 TARIFF & REGULATORY ANALYSIS 94 6.11.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00 94 6.11.1.1 US 94 6.11.1.2 European Union 94 6.11.1.3 Asia Pacific 94 6.11.2 REGULATORY LANDSCAPE 95 6.11.2.1 North America 95 6.11.2.1.1 US 95 6.11.2.1.2 Canada 97 6.11.2.2 Europe 97 6.11.2.3 Asia Pacific 99 6.11.2.3.1 Japan 99 6.11.2.3.2 China 100 6.11.2.3.3 India 100 6.11.2.4 Latin America 101 6.11.2.4.1 Brazil 101   6.11.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 6.11.4 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 104 6.12 KEY CONFERENCES & EVENTS, 2025–2026 105 6.13 INVESTMENT & FUNDING SCENARIO 106 6.14 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET 107 6.15 IMPACT OF 2025 US TARIFF ON MOLECULAR CYTOGENETICS MARKET 109 6.15.1 INTRODUCTION 109 6.15.2 KEY TARIFF RATES 109 6.15.3 PRICE IMPACT ANALYSIS 111 6.15.4 KEY IMPACT ON COUNTRIES/REGIONS 112 6.15.4.1 North America 112 6.15.4.1.1 US 112 6.15.4.2 Europe 113 6.15.4.3 Asia Pacific 113 6.15.5 IMPACT OF END-USE INDUSTRIES 114 6.15.5.1 Clinical & diagnostic laboratories 114 6.15.5.2 Academic & research institutes 114 6.15.5.3 Pharmaceutical & biotechnology companies 114 7 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE 115 7.1 INTRODUCTION 116 7.2 KITS & REAGENTS 116 7.2.1 TESTING KITS 120 7.2.1.1 Standardized and integrated kit workflows to propel market growth 120 7.2.2 PROBES 124 7.2.2.1 Advances in oligonucleotide probe chemistry, multiplexing, and regulatory-driven product modernization to boost market 124 7.2.3 FLUORESCENT AFFINITY REAGENTS 127 7.2.3.1 Improved fluorochrome chemistry and pre-validated conjugates paired with advanced spectral imaging to drive growth 127 7.2.4 OTHER KITS & REAGENTS 131 7.3 CONSUMABLES 134 7.3.1 STANDARDIZATION AND EXPANDING CLINICAL APPLICATIONS TO PROMOTE MARKET GROWTH 134 7.4 INSTRUMENTS 138 7.4.1 AUTOMATION, AI-ENABLED IMAGING, AND INTEGRATED PLATFORMS TO DRIVE MARKET 138 7.5 SOFTWARE & SERVICES 141 7.5.1 AI INTEGRATION, WORKFLOW STANDARDIZATION, AND CLOUD-ENABLED DATA MANAGEMENT TO DRIVE MARKET 141   8 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE 145 8.1 INTRODUCTION 146 8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 146 8.2.1 INTEGRATION OF FISH AND ADVANCED IMAGING TECHNOLOGIES TO DRIVE GROWTH 146 8.3 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) 150 8.3.1 BETTER CLINICAL ACCEPTANCE AND IMPROVED TECHNOLOGICAL INTEGRATION TO PROPEL MARKET GROWTH 150 8.4 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 153 8.4.1 ENHANCED PROBE TECHNOLOGY AND BETTER WORKFLOW AUTOMATION TO BOOST MARKET GROWTH 153 8.5 OTHER TECHNIQUES 157 9 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION 161 9.1 INTRODUCTION 162 9.2 GENETIC DISORDERS 162 9.2.1 EXPANDED CLINICAL GUIDELINES AND IMPROVED CMA/FISH TECHNOLOGIES TO PROPEL MARKET GROWTH 162 9.3 CANCER 166 9.3.1 RISING CANCER RESEARCH AND INCREASING USE OF AUTOMATED CYTOGENETIC PLATFORMS TO DRIVE MARKET 166 9.4 PERSONALIZED MEDICINE 169 9.4.1 STRATEGIC COLLABORATIONS AND BIOMARKER-DRIVEN CYTOGENETIC TESTING TO ACCELERATE MARKET GROWTH 169 9.5 OTHER APPLICATIONS 173 10 MOLECULAR CYTOGENETICS MARKET, BY END USER 177 10.1 INTRODUCTION 178 10.2 CLINICAL & DIAGNOSTIC LABORATORIES 178 10.2.1 INVESTMENT IN AUTOMATION AND INDUSTRY PARTNERSHIPS TO DRIVE MARKET GROWTH 178 10.3 ACADEMIC & RESEARCH INSTITUTES 182 10.3.1 STRATEGIC ACADEMIA–INDUSTRY COLLABORATIONS TO AUGMENT MARKET GROWTH 182 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185 10.4.1 STRATEGIC ACQUISITIONS AND PRECISION MEDICINE INTEGRATION TO FUEL MARKET GROWTH 185 10.5 OTHER END USERS 189   11 MOLECULAR CYTOGENETICS MARKET, BY REGION 193 11.1 INTRODUCTION 194 11.2 NORTH AMERICA 194 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 194 11.2.2 US 199 11.2.2.1 US to dominate North American molecular cytogenetics market during study period 199 11.2.3 CANADA 202 11.2.3.1 Increasing cancer burden and expanding application of cytogenetics technology in oncology to drive market 202 11.3 EUROPE 205 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 205 11.3.2 GERMANY 210 11.3.2.1 Dynamic convergence of research excellence, clinical adoption, and industry collaboration to augment market growth 210 11.3.3 UK 213 11.3.3.1 Strong governmental support for genomics research and advanced healthcare infrastructure to aid market growth 213 11.3.4 FRANCE 215 11.3.4.1 Increasing government investment in pharmaceutical industry to support market growth 215 11.3.5 ITALY 218 11.3.5.1 Rising research activities in pharma R&D to boost market growth 218 11.3.6 SPAIN 221 11.3.6.1 Well-established network of research centers and universities to boost clinical and diagnostic research 221 11.3.7 REST OF EUROPE 224 11.4 ASIA PACIFIC 227 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 227 11.4.2 CHINA 232 11.4.2.1 Development of advanced healthcare infrastructure and government support for genomics research to propel growth 232 11.4.3 JAPAN 235 11.4.3.1 Technological adoption and increased clinical programs to favor market growth 235 11.4.4 INDIA 238 11.4.4.1 Rising awareness of cancer and genetic disorders to support market growth 238 11.4.5 AUSTRALIA 241 11.4.5.1 Progressive translational research, advanced diagnostic integration, and cross-institutional collaborations to fuel growth 241 11.4.6 SOUTH KOREA 244 11.4.6.1 Technological innovation and high demand for precision medicines to aid market growth 244 11.4.7 REST OF ASIA PACIFIC 247 11.5 LATIN AMERICA 250 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 250 11.5.2 BRAZIL 254 11.5.2.1 Increased number of public-private collaborations to focus on strategic market expansions 254 11.5.3 MEXICO 257 11.5.3.1 Strengthening genomic infrastructure and technology integration to support market growth 257 11.5.4 REST OF LATIN AMERICA 260 11.6 MIDDLE EAST 263 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 263 11.6.2 GCC COUNTRIES 267 11.6.2.1 Kingdom of Saudi Arabia 270 11.6.2.1.1 Growing healthcare expenditure to boost market growth 270 11.6.2.2 UAE 273 11.6.2.2.1 Rising government support and incorporation of ISH technologies by hospitals to aid market growth 273 11.6.2.3 Rest of GCC countries 276 11.6.3 REST OF MIDDLE EAST 279 11.7 AFRICA 282 11.7.1 GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR GENETIC TESTING TO PROPEL GROWTH 282 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 282 12 COMPETITIVE LANDSCAPE 286 12.1 INTRODUCTION 286 12.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 286 12.3 REVENUE ANALYSIS, 2020–2024 289 12.4 MARKET SHARE ANALYSIS, 2024 290 12.5 COMPANY VALUATION & FINANCIAL METRICS 292 12.5.1 FINANCIAL METRICS 292 12.5.2 COMPANY VALUATION 292 12.6 BRAND/PRODUCT COMPARISON 293 12.6.1 F. HOFFMANN-LA ROCHE LTD. 293 12.6.2 DANAHER CORPORATION 294 12.6.3 AGILENT TECHNOLOGIES, INC. 294 12.6.4 ABBOTT 294 12.6.5 THERMO FISHER SCIENTIFIC INC. 294 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 294 12.7.1 STARS 294 12.7.2 EMERGING LEADERS 294 12.7.3 PERVASIVE PLAYERS 295 12.7.4 PARTICIPANTS 295 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 296 12.7.5.1 Company footprint 296 12.7.5.2 Region footprint 296 12.7.5.3 Product & service footprint 297 12.7.5.4 Technique footprint 298 12.7.5.5 Application footprint 298 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 299 12.8.1 PROGRESSIVE COMPANIES 299 12.8.2 RESPONSIVE COMPANIES 299 12.8.3 DYNAMIC COMPANIES 299 12.8.4 STARTING BLOCKS 299 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 301 12.8.5.1 Detailed list of key startups/SMEs 301 12.8.5.2 Competitive benchmarking of key startups/SMEs 302 12.9 COMPETITIVE SCENARIO 303 12.9.1 PRODUCT LAUNCHES & APPROVALS 303 12.9.2 DEALS 304 12.9.3 EXPANSIONS 305 12.9.4 OTHER DEVELOPMENTS 305 13 COMPANY PROFILES 306 13.1 KEY PLAYERS 306 13.1.1 F. HOFFMANN-LA ROCHE LTD. 306 13.1.1.1 Business overview 306 13.1.1.2 Products/Services offered 307 13.1.1.3 Recent developments 309 13.1.1.3.1 Product launches & approvals 309 13.1.1.4 MnM view 310 13.1.1.4.1 Key strengths 310 13.1.1.4.2 Strategic choices 310 13.1.1.4.3 Weaknesses & competitive threats 310 13.1.2 DANAHER CORPORATION 311 13.1.2.1 Business overview 311 13.1.2.2 Products/Services offered 312 13.1.2.3 Recent developments 314 13.1.2.3.1 Product launches 314 13.1.2.3.2 Deals 315 13.1.2.4 MnM view 315 13.1.2.4.1 Key strengths 315 13.1.2.4.2 Strategic choices 315 13.1.2.4.3 Weaknesses & competitive threats 316   13.1.3 AGILENT TECHNOLOGIES, INC. 317 13.1.3.1 Business overview 317 13.1.3.2 Products/Services offered 318 13.1.3.3 Recent developments 320 13.1.3.3.1 Product launches 320 13.1.3.3.2 Deals 321 13.1.3.3.3 Other developments 321 13.1.3.4 MnM view 322 13.1.3.4.1 Key strengths 322 13.1.3.4.2 Strategic choices 322 13.1.3.4.3 Weaknesses & competitive threats 322 13.1.4 ABBOTT 323 13.1.4.1 Business overview 323 13.1.4.2 Products/Services offered 324 13.1.4.3 MnM view 325 13.1.4.3.1 Key strengths 325 13.1.4.3.2 Strategic choices 325 13.1.4.3.3 Weaknesses & competitive threats 325 13.1.5 THERMO FISHER SCIENTIFIC INC. 326 13.1.5.1 Business overview 326 13.1.5.2 Products/Services offered 327 13.1.5.3 Recent developments 329 13.1.5.3.1 Product launches 329 13.1.5.3.2 Deals 329 13.1.5.4 MnM view 330 13.1.5.4.1 Key strengths 330 13.1.5.4.2 Strategic choices 330 13.1.5.4.3 Weaknesses & competitive threats 330 13.1.6 ILLUMINA, INC. 331 13.1.6.1 Business overview 331 13.1.6.2 Products/Services offered 332 13.1.6.3 Recent developments 333 13.1.6.3.1 Deals 333 13.1.6.3.2 Expansions 334 13.1.7 REVVITY 335 13.1.7.1 Business overview 335 13.1.7.2 Products/Services offered 336 13.1.7.3 Recent developments 337 13.1.7.3.1 Product launches 337 13.1.7.3.2 Deals 338   13.1.8 PACBIO 339 13.1.8.1 Business overview 339 13.1.8.2 Products/Services offered 340 13.1.8.3 Recent developments 341 13.1.8.3.1 Deals 341 13.1.8.3.2 Expansions 342 13.1.9 BIO-RAD LABORATORIES, INC. 343 13.1.9.1 Business overview 343 13.1.9.2 Products/Services offered 344 13.1.10 BIO-TECHNE 347 13.1.10.1 Business overview 347 13.1.10.2 Products/Services offered 348 13.1.10.3 Recent developments 349 13.1.10.3.1 Product launches 349 13.1.10.3.2 Deals 350 13.1.11 GENE DX, LLC 351 13.1.11.1 Business overview 351 13.1.11.2 Products/Services offered 352 13.1.11.3 Recent developments 352 13.1.11.3.1 Deals 352 13.1.12 INSIGHT MOLECULAR DIAGNOSTICS INC. 353 13.1.12.1 Business overview 353 13.1.12.2 Products/Services offered 354 13.1.13 BIOVIEW 355 13.1.13.1 Business overview 355 13.1.13.2 Products/Services offered 355 13.2 OTHER PLAYERS 357 13.2.1 OXFORD GENE TECHNOLOGY IP LIMITED 357 13.2.2 APPLIED SPECTRAL IMAGING 358 13.2.3 CYTOTEST INC. 359 13.2.4 KROMATID 360 13.2.5 GENIAL GENETIC SOLUTIONS LTD. 361 13.2.6 CYTOGNOMIX INC. 362 13.2.7 METASYSTEMS 363 13.2.8 SCIGENE CORPORATION 364 13.2.9 BIOMODAL 365 13.2.10 BIOCARE MEDICAL, LLC 366 13.2.11 BIODOT 367 13.2.12 ONCODNA 368   14 APPENDIX 369 14.1 DISCUSSION GUIDE 369 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 373 14.3 CUSTOMIZATION OPTIONS 375 14.4 RELATED REPORTS 375 14.5 AUTHOR DETAILS 376
圖表清單 List of Tables & Figures
TABLE 1 MOLECULAR CYTOGENETICS MARKET: INCLUSIONS & EXCLUSIONS 36 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 47 TABLE 3 MOLECULAR CYTOGENETICS MARKET: RISK ANALYSIS 50 TABLE 4 IMPACT ANALYSIS OF MOLECULAR CYTOGENETICS MARKET DYNAMICS 65 TABLE 5 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 74 TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD) 76 TABLE 7 AVERAGE SELLING PRICE TREND OF KITS, BY REGION, 2022–2024 (USD) 77 TABLE 8 AVERAGE SELLING PRICE TREND OF REAGENTS, BY REGION, 2022–2024 (USD) 77 TABLE 9 NUMBER OF PATENTS FILED IN MOLECULAR CYTOGENETICS MARKET, BY DOCUMENT TYPE, 2014–2024 79 TABLE 10 LIST OF KEY PATENTS IN MOLECULAR CYTOGENETICS MARKET, 2023–2025 81 TABLE 11 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 82 TABLE 12 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 83 TABLE 13 MOLECULAR CYTOGENETICS MARKET: ROLE IN ECOSYSTEM 88 TABLE 14 MOLECULAR CYTOGENETICS MARKET: PORTER’S FIVE FORCES 89 TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 92 TABLE 16 KEY BUYING CRITERIA, BY END USER 93 TABLE 17 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00 95 TABLE 18 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 95 TABLE 19 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 97 TABLE 20 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 99 TABLE 21 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 100 TABLE 22 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 100 TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 27 LIST OF KEY CONFERENCES & EVENTS IN MOLECULAR CYTOGENETICS MARKET, JANUARY 2025–DECEMBER 2026 105 TABLE 28 KEY PLAYERS IMPLEMENTING AI/GEN AI IN MOLECULAR CYTOGENETICS MARKET 108 TABLE 29 US ADJUSTED RECIPROCAL TARIFF RATES 109 TABLE 30 EXPORTS AND IMPORTS, BY REGION 110 TABLE 31 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO MOLECULAR CYTOGENETICS 111 TABLE 32 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 112 TABLE 33 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 116 TABLE 34 MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 117 TABLE 35 MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 36 NORTH AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 37 EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 38 ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 39 LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 40 MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 41 GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 42 MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 43 NORTH AMERICA: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 44 EUROPE: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 45 ASIA PACIFIC: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 46 LATIN AMERICA: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 47 MIDDLE EAST: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 48 GCC COUNTRIES: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 49 MOLECULAR CYTOGENETICS PROBES MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 50 NORTH AMERICA: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 51 EUROPE: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 52 ASIA PACIFIC: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 53 LATIN AMERICA: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 54 MIDDLE EAST: MOLECULAR CYTOGENETICS PROBES MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 55 GCC COUNTRIES: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 56 MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 57 NORTH AMERICA: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 58 EUROPE: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 59 ASIA PACIFIC: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 60 LATIN AMERICA: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 61 MIDDLE EAST: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 62 GCC COUNTRIES: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 63 OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 64 NORTH AMERICA: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 65 EUROPE: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 66 ASIA PACIFIC: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 67 LATIN AMERICA: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 68 MIDDLE EAST: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 69 GCC COUNTRIES: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 70 MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 71 NORTH AMERICA: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 72 EUROPE: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 73 ASIA PACIFIC: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 74 LATIN AMERICA: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 75 MIDDLE EAST: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 76 GCC COUNTRIES: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 77 MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 78 NORTH AMERICA: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 79 EUROPE: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 80 ASIA PACIFIC: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 81 LATIN AMERICA: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 82 MIDDLE EAST: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 83 GCC COUNTRIES: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 84 MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 85 NORTH AMERICA: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 86 EUROPE: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 87 ASIA PACIFIC: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 88 LATIN AMERICA: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 89 MIDDLE EAST: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 90 GCC COUNTRIES: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 91 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 146 TABLE 92 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2023–2030 (USD MILLION) 147 TABLE 93 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 94 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 95 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 96 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 97 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2023–2030 (USD MILLION) 149 TABLE 98 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 99 MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY REGION, 2023–2030 (USD MILLION) 150 TABLE 100 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 101 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 102 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 103 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 104 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY REGION, 2023–2030 (USD MILLION) 153 TABLE 105 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 106 MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2023–2030 (USD MILLION) 154 TABLE 107 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 108 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 109 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 110 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 111 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 112 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 113 MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 114 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 115 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 116 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 117 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 118 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 119 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 120 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 162 TABLE 121 MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 122 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 123 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 124 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 125 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 126 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 127 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 128 MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 129 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 130 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 131 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 132 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 133 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 134 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 135 MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 136 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 137 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 138 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 139 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 140 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 141 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 142 MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 143 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 144 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 145 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 146 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 147 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 148 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 149 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 150 MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 151 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 152 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 153 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 154 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 155 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 156 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 157 MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 158 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 159 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 160 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 161 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 162 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 185 TABLE 163 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 164 MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 165 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 166 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 167 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 168 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 169 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 170 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 171 MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 172 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 173 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 174 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 175 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 176 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 177 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 178 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 179 NORTH AMERICA: KEY MACROINDICATORS 195 TABLE 180 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 181 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 197 TABLE 182 NORTH AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 183 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 198 TABLE 184 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 185 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 186 US: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 200 TABLE 187 US: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 188 US: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 201 TABLE 189 US: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201 TABLE 190 US: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 202 TABLE 191 CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 203 TABLE 192 CANADA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 203 TABLE 193 CANADA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 204 TABLE 194 CANADA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 204 TABLE 195 CANADA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 205 TABLE 196 EUROPE: KEY MACROINDICATORS 206 TABLE 197 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 198 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 207 TABLE 199 EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 200 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 208 TABLE 201 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 202 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 203 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 210 TABLE 204 GERMANY: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 205 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 211 TABLE 206 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 207 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 208 UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 213 TABLE 209 UK: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 210 UK: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 214 TABLE 211 UK: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 215 TABLE 212 UK: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 213 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 216 TABLE 214 FRANCE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 215 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 217 TABLE 216 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 217 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 218 TABLE 218 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 219 TABLE 219 ITALY: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 220 ITALY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 220 TABLE 221 ITALY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 220 TABLE 222 ITALY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 223 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 222 TABLE 224 SPAIN: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 225 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 223 TABLE 226 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 227 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 228 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 225 TABLE 229 REST OF EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 230 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 226 TABLE 231 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 232 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 233 ASIA PACIFIC: KEY MACROINDICATORS 228 TABLE 234 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 229 TABLE 235 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 230 TABLE 236 ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 237 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 231 TABLE 238 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 239 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 240 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 233 TABLE 241 CHINA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 242 CHINA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 234 TABLE 243 CHINA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 244 CHINA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 245 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 236 TABLE 246 JAPAN: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 247 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 237 TABLE 248 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 249 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 250 INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 239 TABLE 251 INDIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 252 INDIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 240 TABLE 253 INDIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240 TABLE 254 INDIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 255 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 242 TABLE 256 AUSTRALIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 257 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 243 TABLE 258 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 259 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 260 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 245 TABLE 261 SOUTH KOREA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 262 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 246 TABLE 263 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 264 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 265 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 248 TABLE 266 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 267 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 249 TABLE 268 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249 TABLE 269 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 270 LATIN AMERICA: KEY MACROINDICATORS 251 TABLE 271 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 272 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 252 TABLE 273 LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 274 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 253 TABLE 275 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 276 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 277 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 255 TABLE 278 BRAZIL: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 279 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 256 TABLE 280 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 281 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 282 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 258 TABLE 283 MEXICO: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 284 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 259 TABLE 285 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 286 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 287 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 261 TABLE 288 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 289 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 262 TABLE 290 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 291 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 292 MIDDLE EAST: KEY MACROINDICATORS 264 TABLE 293 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION) 264 TABLE 294 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 265 TABLE 295 MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 296 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 266 TABLE 297 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 266 TABLE 298 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 267 TABLE 299 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 267 TABLE 300 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 268 TABLE 301 GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 302 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 269 TABLE 303 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 269 TABLE 304 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 270 TABLE 305 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 271 TABLE 306 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 307 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 272 TABLE 308 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 309 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 273 TABLE 310 UAE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 274 TABLE 311 UAE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 312 UAE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 275 TABLE 313 UAE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 275 TABLE 314 UAE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 315 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 277 TABLE 316 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 317 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 278 TABLE 318 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 319 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 279 TABLE 320 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 279 TABLE 321 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 322 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 280 TABLE 323 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 324 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 281 TABLE 325 AFRICA: KEY MACROINDICATORS 283 TABLE 326 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 283 TABLE 327 AFRICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 328 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 284 TABLE 329 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 330 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 285 TABLE 331 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN MOLECULAR CYTOGENETICS MARKET, JANUARY 2022–SEPTEMBER 2025 286 TABLE 332 MOLECULAR CYTOGENETICS MARKET: DEGREE OF COMPETITION 290 TABLE 333 MOLECULAR CYTOGENETICS MARKET: REGION FOOTPRINT 296 TABLE 334 MOLECULAR CYTOGENETICS MARKET: PRODUCT & SERVICE FOOTPRINT 297 TABLE 335 MOLECULAR CYTOGENETICS MARKET: TECHNIQUE FOOTPRINT 298 TABLE 336 MOLECULAR CYTOGENETICS MARKET: APPLICATION FOOTPRINT 298 TABLE 337 MOLECULAR CYTOGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 301 TABLE 338 MOLECULAR CYTOGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION 302 TABLE 339 MOLECULAR CYTOGENETICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–SEPTEMBER 2025 303 TABLE 340 MOLECULAR CYTOGENETICS MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 304 TABLE 341 MOLECULAR CYTOGENETICS MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 305 TABLE 342 MOLECULAR CYTOGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 305 TABLE 343 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 306 TABLE 344 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 307 TABLE 345 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–SEPTEMBER 2025 309 TABLE 346 DANAHER CORPORATION: COMPANY OVERVIEW 311 TABLE 347 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 312 TABLE 348 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 314 TABLE 349 DANAHER CORPORATION: DEALS, JANUARY 2022–SEPTEMBER 2025 315 TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 317 TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 318 TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 320 TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 321 TABLE 354 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025 321 TABLE 355 ABBOTT: COMPANY OVERVIEW 323 TABLE 356 ABBOTT: PRODUCTS/SERVICES OFFERED 324 TABLE 357 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 326 TABLE 358 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 327 TABLE 359 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 329 TABLE 360 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 329 TABLE 361 ILLUMINA, INC.: COMPANY OVERVIEW 331 TABLE 362 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 332 TABLE 363 ILLUMINA, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 333 TABLE 364 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 334 TABLE 365 REVVITY: COMPANY OVERVIEW 335 TABLE 366 REVVITY: PRODUCTS/SERVICES OFFERED 336 TABLE 367 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 337 TABLE 368 REVVITY: DEALS, JANUARY 2022–SEPTEMBER 2025 338 TABLE 369 PACBIO: COMPANY OVERVIEW 339 TABLE 370 PACBIO: PRODUCTS/SERVICES OFFERED 340 TABLE 371 PACBIO: DEALS, JANUARY 2022–SEPTEMBER 2025 341 TABLE 372 PACBIO: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 342 TABLE 373 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 343 TABLE 374 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 344 TABLE 375 BIO-TECHNE: COMPANY OVERVIEW 347 TABLE 376 BIO-TECHNE: PRODUCTS/SERVICES OFFERED 348 TABLE 377 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 349 TABLE 378 BIO-TECHNE: DEALS, JANUARY 2022–SEPTEMBER 2025 350 TABLE 379 GENE DX, LLC: COMPANY OVERVIEW 351 TABLE 380 GENE DX, LLC: PRODUCTS/SERVICES OFFERED 352 TABLE 381 GENE DX, LLC: DEALS, JANUARY 2022–SEPTEMBER 2025 352 TABLE 382 INSIGHT MOLECULAR DIAGNOSTICS INC.: COMPANY OVERVIEW 353 TABLE 383 INISIGHT MOLECULAR DIAGNOSTICS INC.: PRODUCTS/SERVICES OFFERED 354 TABLE 384 BIOVIEW: COMPANY OVERVIEW 355 TABLE 385 BIOVIEW: PRODUCTS/SERVICES OFFERED 355 TABLE 386 OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW 357 TABLE 387 APPLIED SPECTRAL IMAGING: COMPANY OVERVIEW 358 TABLE 388 CYTOTEST INC.: COMPANY OVERVIEW 359 TABLE 389 KROMATID: COMPANY OVERVIEW 360 TABLE 390 GENIAL GENETIC SOLUTIONS LTD.: COMPANY OVERVIEW 361 TABLE 391 CYTOGNOMIX INC.: COMPANY OVERVIEW 362 TABLE 392 METASYSTEMS: COMPANY OVERVIEW 363 TABLE 393 SCIGENE CORPORATION: COMPANY OVERVIEW 364 TABLE 394 BIOMODAL: COMPANY OVERVIEW 365 TABLE 395 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 366 TABLE 396 BIODOT: COMPANY OVERVIEW 367 TABLE 397 ONCODNA: COMPANY OVERVIEW 368 FIGURE 1 MOLECULAR CYTOGENETICS MARKET SEGMENTATION & REGIONAL SCOPE 35 FIGURE 2 MOLECULAR CYTOGENETICS MARKET: YEARS CONSIDERED 36 FIGURE 3 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN 38 FIGURE 4 MOLECULAR CYTOGENETICS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 40 FIGURE 5 MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 41 FIGURE 6 MOLECULAR CYTOGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024 42 FIGURE 7 REVENUE ANALYSIS: ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD. (2024) 42 FIGURE 8 MOLECULAR CYTOGENETICS MARKET: INSIGHTS FROM KEY PRIMARIES 44 FIGURE 9 MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 45 FIGURE 10 MOLECULAR CYTOGENETICS MARKET: CAGR PROJECTIONS 46 FIGURE 11 MOLECULAR CYTOGENETICS MARKET: DATA TRIANGULATION 48 FIGURE 12 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 51 FIGURE 13 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION) 52 FIGURE 14 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 52 FIGURE 15 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 53 FIGURE 16 MOLECULAR CYTOGENETICS MARKET: REGIONAL ANALYSIS 54 FIGURE 17 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION) 57 FIGURE 18 US AND GENETIC DISORDERS COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 58 FIGURE 19 CLINICAL & DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 59 FIGURE 20 ASIA PACIFIC TO BE FASTEST-GROWING REGION IN GLOBAL MOLECULAR CYTOGENETICS MARKET DURING STUDY PERIOD 60 FIGURE 21 MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 22 NUMBER OF CANCER CASES IN US, 2019–2024 67 FIGURE 23 MOLECULAR CYTOGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71 FIGURE 24 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 75 FIGURE 25 AVERAGE SELLING PRICE OF KITS, BY KEY PLAYER, 2024 (USD) 75 FIGURE 26 AVERAGE SELLING PRICE OF REAGENTS, BY KEY PLAYER, 2024 (USD) 76 FIGURE 27 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD) 77 FIGURE 28 AVERAGE SELLING PRICE OF KITS, BY REGION, 2024 (USD) 78 FIGURE 29 AVERAGE SELLING PRICE OF REAGENTS, BY REGION, 2024 (USD) 78 FIGURE 30 PATENT APPLICATIONS IN MOLECULAR CYTOGENETICS MARKET, JANUARY 2014–DECEMBER 2024 80   FIGURE 31 MOLECULAR CYTOGENETICS MARKET: VALUE CHAIN ANALYSIS 84 FIGURE 32 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ANALYSIS 87 FIGURE 33 MOLECULAR CYTOGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 90 FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 92 FIGURE 35 KEY BUYING CRITERIA, BY END USER 93 FIGURE 36 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 96 FIGURE 37 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 97 FIGURE 38 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 98 FIGURE 39 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99 FIGURE 40 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 101 FIGURE 41 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102 FIGURE 42 FUNDING AND NUMBER OF DEALS IN MOLECULAR CYTOGENETICS MARKET, 2022–2025 (USD MILLION) 106 FIGURE 43 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET 107 FIGURE 44 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 196 FIGURE 45 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 229 FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR CYTOGENETICS MARKET, 2020–2024 (USD MILLION) 289 FIGURE 47 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR CYTOGENETICS MARKET (2024) 290 FIGURE 48 EV/EBITDA OF KEY VENDORS 292 FIGURE 49 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 292 FIGURE 50 MOLECULAR CYTOGENETICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 293 FIGURE 51 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 295 FIGURE 52 MOLECULAR CYTOGENETICS MARKET: COMPANY FOOTPRINT 296 FIGURE 53 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300 FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 307 FIGURE 55 DANAHER CORPORATION: COMPANY SNAPSHOT 312 FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 318 FIGURE 57 ABBOTT: COMPANY SNAPSHOT 324 FIGURE 58 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 327 FIGURE 59 ILLUMINA, INC.: COMPANY SNAPSHOT 332 FIGURE 60 REVVITY: COMPANY SNAPSHOT 336 FIGURE 61 PACBIO: COMPANY SNAPSHOT 340 FIGURE 62 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 344 FIGURE 63 BIO-TECHNE: COMPANY SNAPSHOT 348 FIGURE 64 GENE DX, LLC: COMPANY SNAPSHOT 351 FIGURE 65 INSIGHT MOLECULAR DIAGNOSTICS INC.: COMPANY SNAPSHOT 353

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們